Comparison of anti-angiogenesis drugs targeting VEGF receptors and the VEGF co-mceptor Neuropilin.

被引：0
|
作者：
Mac Gabhann, Feilim [1 ]
Popel, Aleksander S. [1 ]
机构：
[1] Johns Hopkins Univ, Sch Med, Dept Biomed Engn, Baltimore, MD 21205 USA
来源：
FASEB JOURNAL | 2007年 / 21卷 / 06期
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：A747 / A747
页数：1
相关论文
共 50 条
  • [31] SAIF plays anti-angiogenesis via blocking VEGF-VEGFR2-ERK signal in tumor treatment
    Xie, Junye
    Li, Fu
    Cai, Yuling
    Zhang, Jinting
    Zhang, Yibo
    Zhai, Zhaodong
    Su, Zijian
    Chen, Xue
    Lei, Minghua
    Liu, Rongzhan
    Li, Weicai
    Kang, Dianlong
    Chen, Xiaojia
    Hong, An
    HELIYON, 2023, 9 (07)
  • [32] New Pharmaceutical Treatment of Gastric MALT Lymphoma: Anti-angiogenesis Treatment using VEGF Receptor Antibodies and Celecoxib
    Nakamura, Masahiko
    Takahashi, Tetsufumi
    Matsui, Hidenori
    Takahashi, Shinichi
    Murayama, Somay Y.
    Suzuki, Hidekazu
    Tsuchimoto, Kanji
    CURRENT PHARMACEUTICAL DESIGN, 2014, 20 (07) : 1097 - 1103
  • [33] Requisite role of VEGF receptors in angiogenesis of hepatocellular carcinoma: A comparison with angiopoietin/Tie pathway
    Dhar, DK
    Naora, H
    Yamanoi, A
    Ono, T
    Kohno, H
    Otani, H
    Nagasue, N
    ANTICANCER RESEARCH, 2002, 22 (1A) : 379 - 386
  • [34] In vitro evaluation and biodistribution of a 99mTc-labeled anti-VEGF peptide targeting neuropilin-1
    Perret, GY
    Starzec, A
    Hauet, N
    Vergote, J
    Le Pecheur, M
    Vassy, R
    Léger, G
    Verbeke, KA
    Bormans, G
    Nicolas, P
    Verbruggen, AM
    Moretti, JL
    NUCLEAR MEDICINE AND BIOLOGY, 2004, 31 (05) : 575 - 581
  • [35] Imatinib inhibits VEGF-independent angiogenesis by targeting neuropilin 1-dependent ABL1 activation in endothelial cells
    Raimondi, Claudio
    Fantin, Alessandro
    Lampropoulou, Anastasia
    Denti, Laura
    Chikh, Anissa
    Ruhrberg, Christiana
    JOURNAL OF EXPERIMENTAL MEDICINE, 2014, 211 (06): : 1167 - 1183
  • [36] VEGF pathway-targeting drugs induce evasive adaptation by activation of neuropilin-1/cMet in colon cancer cells
    Tomida, Chisato
    Yamagishi, Naoko
    Nagano, Hikaru
    Uchida, Takayuki
    Ohno, Ayako
    Hirasaka, Katsuya
    Nikawa, Takeshi
    Teshima-Kondo, Shigetada
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2018, 52 (04) : 1350 - 1362
  • [37] Peptide-mediated anti-VEGF siRNA delivery targeting angiogenesis in glioblastoma and endothelial cells
    Shubina, A.
    Egorova, A.
    Bogacheva, M.
    Maretina, M.
    Baranov, V.
    Kiselev, A.
    HUMAN GENE THERAPY, 2013, 24 (12) : A70 - A70
  • [38] Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent
    Mendel, DB
    Laird, AD
    Smolich, BD
    Blake, RA
    Liang, CX
    Hannah, AL
    Shaheen, RM
    Ellis, LM
    Weitman, S
    Shawver, LK
    Cherrington, JM
    ANTI-CANCER DRUG DESIGN, 2000, 15 (01): : 29 - 41
  • [39] K20E, an Oxidative-coupling Compound of Methyl Caffeate, Exhibits Anti-angiogenesis Activities through Down-Regulations of VEGF and VEGF Receptor-2.
    Wu, C.
    Pan, C.
    Lin
    MOLECULAR BIOLOGY OF THE CELL, 2014, 25
  • [40] Recent advances in ocular drug delivery systems and targeting VEGF receptors for management of ocular angiogenesis: A comprehensive review
    Soumya Narayana
    Mohammed Gulzar Ahmed
    B. H. Jaswanth Gowda
    Pallavi K. Shetty
    Arfa Nasrine
    M. Thriveni
    Nadira Noushida
    A. Sanjana
    Future Journal of Pharmaceutical Sciences, 7
12345